Sanofi ADR(SNY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 5:21 PM ET (Korea 10/24 06:21)
Full metrics table
| Index | - | P/E | 21.43 | EPS (ttm) | 1.94 | Insider Own | - | Shs Outstand | 2.43B | Perf Week | 2.44% |
| Market Cap | 99.15B | Forward P/E | 8.08 | EPS next Y | 6.55% | Insider Trans | - | Shs Float | 2.38B | Perf Month | 1.61% |
| Enterprise Value | 119.26B | PEG | 1.36 | EPS next Q | 1.56 | Inst Own | 7.98% | Short Float | 0.45% | Perf Quarter | -5.45% |
| Income | 4.69B | P/S | 1.85 | EPS this Y | 3.5% | Inst Trans | -0.55% | Short Ratio | 3.56 | Perf Half Y | -11.07% |
| Sales | 53.47B | P/B | 1.28 | EPS next 5Y | 5.96% | ROA | 3.12% | Short Interest | 10.61M | Perf YTD | -14.16% |
| Book/sh | 32.59 | P/C | 13.66 | EPS past 3/5Y | -11.86% -15.52% | ROE | 5.7% | 52W High | -21.03% ($52.68) | Perf Year | -15.99% |
| Cash/sh | 3.05 | P/FCF | 8.23 | Sales past 3/5Y | 2.9% 3.69% | ROIC | 4.8% | 52W Low | 6.48% ($39.07) | Perf 3Y | -20.11% |
| Dividend Est. | $2.4 (5.77%) | EV/EBITDA | 5.3 | EPS Y/Y TTM | -30.9% | Gross Margin | 66.29% | Volatility(W/M) | 1.8% 1.64% | Perf 5Y | -16.22% |
| Dividend TTM | 2.42 | EV/Sales | 2.23 | Sales Y/Y TTM | 23.68% | Oper. Margin | 27.17% | ATR (14) | 0.85 | Perf 10Y | 10.79% |
| Dividend Ex-Date | 2026/5/4 | Quick Ratio | 0.64 | EPS Q/Q | -32.22% | Profit Margin | 8.78% | RSI (14) | 53.42 | Recom | 2.1 |
| Dividend Gr. 3/5Y | 8.45% 5.14% | Current Ratio | 0.99 | Sales Q/Q | 18.71% | SMA20 | 2.93% ($40.42) | Beta | 0.29 | Target Price | $49.8 |
| Payout | 73.36% | Debt/Eq | 0.34 | Earnings | 2026/10/30 | SMA50 | -1.93% ($42.42) | Rel Volume | 0.67 | Prev Close | $41.96 |
| Employees | 76493 | LT Debt/Eq | 0.24 | EPS/Sales Surpr. | 3.11% 3.35% | SMA200 | -6.43% ($44.46) | Avg Volume(3M) | 2.98M | Price | $41.6 |
| IPO | 2002/7/1 | Option/Short | Yes/Yes | Trades | 14850 | Volume | 2,011,588 | Change | -0.86% |
💊 This is a U.S. ADR of Sanofi, a global large-cap pharmaceutical company headquartered in France. It supplies treatments for immune and inflammatory diseases, vaccines, and consumer healthcare products to global markets, and maintains a stable revenue stream centered on its specialty care portfolio, including Dupixent, as well as influenza and respiratory vaccines.
Over the past 1 year, on the lower side
21% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
Next earnings report: October 30
4 days to go.
SNY earns at a steady pace
Of every $100 in sales, $27.17 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +3.5% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $808. Peers typically go for $1,515.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -16.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 5.77% annually in dividends.
Tap to view numbers
Institutions barely hold it
Institutions hold 8.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #13 of 21 in the industry
Based on market cap of $99B.
Earnings Analysis · 7/30 Sanofi ($SNY) 2026 Q2 Earnings Analysis — Guidance Raised on Dupixent and New Product Surge; Pipeline Cleanup Drags on After-Hours Trading Investing Guides · 4/11 2026 U.S. High-Dividend Stock Guide — How to Screen Out the Traps Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is SNY?
SNY belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of SNY?
The market cap of SNY is approximately $99.2B, ranking 164 within its sector.
Does SNY pay dividends?
SNY has a dividend yield of approximately 5.77%, with an annual dividend of $2.40.
What is the P/E ratio of SNY?
SNY has a P/E ratio of approximately 21.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SNY?
SNY has recorded a 52-week high of $52.68 and a low of $39.07.
